{"id":4295,"date":"2025-08-07T10:35:28","date_gmt":"2025-08-07T07:35:28","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=4295"},"modified":"2025-08-07T10:36:39","modified_gmt":"2025-08-07T07:36:39","slug":"keros-therapeutics-focuses-on-advancing-ker-065-for-duchenne-muscular-dystrophy-dmd","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/fr\/keros-therapeutics-focuses-on-advancing-ker-065-for-duchenne-muscular-dystrophy-dmd\/","title":{"rendered":"Keros Therapeutics se concentre sur l&#039;avancement du KER-065 pour la dystrophie musculaire de Duchenne (DMD)"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Keros Therapeutics a annonc\u00e9 un r\u00e9alignement strat\u00e9gique visant \u00e0 r\u00e9affecter les ressources au d\u00e9veloppement de son programme clinique cl\u00e9, KER-065 pour la dystrophie musculaire de Duchenne (DMD).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Keros a annonc\u00e9 plusieurs changements au sein de son conseil d&#039;administration et de sa direction afin de soutenir la rationalisation de sa vision et de sa strat\u00e9gie op\u00e9rationnelle. Ces actions refl\u00e8tent la confiance de Keros dans le potentiel th\u00e9rapeutique de KER-065 et lui permettront de mieux remplir sa mission\u00a0: offrir aux patients des b\u00e9n\u00e9fices significatifs et potentiellement modificateurs de la maladie.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u00ab Conform\u00e9ment \u00e0 l&#039;engagement de Keros \u00e0 cr\u00e9er de la valeur pour les actionnaires et les patients, nous avons d\u00e9cid\u00e9 de rationaliser nos op\u00e9rations et de nous concentrer exclusivement sur le d\u00e9veloppement de KER-065, un actif qui, selon nous, pr\u00e9sente un potentiel th\u00e9rapeutique pour les personnes atteintes de dystrophie musculaire de Duchenne (\u00ab DMD \u00bb) \u00bb, a d\u00e9clar\u00e9 Jasbir S. Seehra, Ph.D., PDG de Keros Therapeutics. \u00ab En donnant la priorit\u00e9 \u00e0 notre programme clinique le plus prometteur, nous pr\u00e9voyons que Keros fonctionnera avec plus de pr\u00e9cision et d&#039;urgence afin de g\u00e9n\u00e9rer davantage de valeur pour les actionnaires. Gr\u00e2ce \u00e0 une strat\u00e9gie affin\u00e9e, une direction rationalis\u00e9e et une base clinique solide, nous pensons \u00eatre bien positionn\u00e9s pour lancer la prochaine phase de d\u00e9veloppement clinique de KER-065. \u00bb<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Apprendre encore plus<\/strong>: <a href=\"https:\/\/dmdwarrior.com\/fr\/keros-therapeutics-announces-initial-topline-results-from-the-phase-1-clinical-trial-of-ker-065-in-healthy-volunteers\/\">Keros Therapeutics annonce les premiers r\u00e9sultats de l&#039;essai clinique de phase 1 du KER-065 chez des volontaires sains<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">La Soci\u00e9t\u00e9 a pr\u00e9c\u00e9demment annonc\u00e9 les premiers r\u00e9sultats de l&#039;essai clinique de phase 1 du KER-065 chez des volontaires sains. Cet essai a atteint des objectifs cl\u00e9s en mati\u00e8re de s\u00e9curit\u00e9, de tol\u00e9rance, de pharmacocin\u00e9tique et de pharmacodynamie. La Soci\u00e9t\u00e9 estime que ces donn\u00e9es solides justifient la progression du programme vers un essai clinique de phase 2 du KER-065 chez des patients atteints de DMD, essai qui devrait d\u00e9buter au premier trimestre 2026, sous r\u00e9serve d&#039;une interaction r\u00e9glementaire positive.<\/p>","protected":false},"excerpt":{"rendered":"<p>Keros Therapeutics announced a strategic realignment designed to reallocate resources towards the development of its key clinical program, KER-065 for Duchenne muscular dystrophy (DMD). Keros announced several Board of Directors and leadership transitions intended to support the Company\u2019s streamlined vision and operational focus. These actions reflect Keros\u2019 confidence in the therapeutic potential of KER-065 and [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4297,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[337,336],"class_list":["post-4295","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-ker-065","tag-keros-therapeutics"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts\/4295","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/comments?post=4295"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts\/4295\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/media\/4297"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/media?parent=4295"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/categories?post=4295"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/tags?post=4295"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}